Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.2K
The pathophysiology of pneumonia involves the following steps:
4.2K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

1.2K
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

665
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
665
Pneumonia IV: Management01:28

Pneumonia IV: Management

1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Surgical Outcomes and Perioperative Laboratory Parameters Following Minimally Invasive Plate Osteosynthesis versus Conventional Plating in Long Bone Fractures.

Journal of orthopaedic case reports·2026
Same author

Isolation and screening of silicate-solubilizing bacteria for enhanced desilicification of silica-containing agro-residues.

Biodegradation·2026
Same author

Unravelling the potential of Vitex negundo leaf extract in LPS-induced acute lung injury in mice through modulation of the TLR-4/NF-κB p65/iNOS pathway: Insights from integrated phytochemical characterization, in silico, and in vivo analysis.

Tissue & cell·2026
Same author

Piperine Protects Against Arsenic Trioxide-Induced Cardiotoxicity in Rats: A Biochemical and Electrocardiography Study.

Current cardiology reviews·2026
Same author

Comparison of Cemented Versus Cementless Total Hip Arthroplasty in Elderly Patients: A Prospective Cohort Study.

Journal of orthopaedic case reports·2026
Same author

Comorbid Depression in Atopic Dermatitis-The Itch-to-Brain Circuitry Theory.

JAMA psychiatry·2026

Related Experiment Video

Updated: Apr 3, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.6K

Atorvastatin along with imipenem attenuates acute lung injury in sepsis through decrease in inflammatory mediators

Soumen Choudhury1, Kannan Kandasamy1, Bhojane Somnath Maruti1

  • 1Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, 243122 Bareilly, Uttar Pradesh, India.

European Journal of Pharmacology
|September 17, 2015
PubMed
Summary

Combined atorvastatin and imipenem treatment reduced bacterial load and inflammation in sepsis-induced lung injury in mice. This approach shows therapeutic potential for mitigating sepsis complications in the lungs.

Keywords:
AtorvastatinImipenemLung injurySepsis

More Related Videos

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

11.5K
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

27.3K

Related Experiment Videos

Last Updated: Apr 3, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
05:56

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats

Published on: February 20, 2021

2.6K
Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

11.5K
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
11:07

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

27.3K

Area of Science:

  • Sepsis research
  • Pulmonary medicine
  • Pharmacology

Background:

  • Sepsis frequently leads to multi-organ dysfunction, with the lungs being particularly vulnerable.
  • Sepsis-induced lung injury (SILI) is a critical complication characterized by inflammation and edema.
  • Effective therapeutic strategies for SILI remain a significant clinical challenge.

Purpose of the Study:

  • To investigate the efficacy of combined atorvastatin and imipenem treatment in attenuating sepsis-induced lung injury in a mouse model.
  • To assess the impact of this combined therapy on key indicators of lung injury and inflammation.

Main Methods:

  • Sepsis was induced using the cecal ligation and puncture (CLP) model in mice.
  • Lung injury was evaluated by measuring lung edema, vascular permeability, inflammatory cell infiltration, and cytokine levels in bronchoalveolar lavage fluid (BALF).
  • Bacterial load, myeloperoxidase (MPO) activity, intercellular adhesion molecule-1 (ICAM-1) mRNA, and inducible nitric oxide synthase (iNOS) expression were assessed.

Main Results:

  • Combined atorvastatin and imipenem treatment significantly reduced lung bacterial load and levels of pro-inflammatory cytokines (IL-1β, TNFα) in BALF.
  • Pulmonary edema markers, including microvascular leakage and wet-dry weight ratio, were attenuated.
  • Reduced MPO activity and ICAM-1 mRNA expression indicated decreased inflammatory cell infiltration and adhesion. iNOS expression was also downregulated.

Conclusions:

  • Combined therapy with atorvastatin and imipenem effectively dampened the inflammatory response and reduced bacterial burden in sepsis-induced lung injury.
  • This combination therapy demonstrates promising therapeutic potential for managing sepsis-induced lung injury in preclinical models.
  • Further research may explore the clinical application of this combined treatment strategy for sepsis patients.